LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

Kodu・Aktsiate loetelu・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Avatud

SektorTervishoid

583.61 -0.21

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

570.81

Max

592.54

Põhinäitajad
By Trading Economics
Sissetulek	-72M -114M
Müük	74M 287M
Aktsiakasum	-4.956
Kasumimarginaal	-39.75
Töötajad	528
EBITDA	-75M -114M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	-1.99% downside

Turustatistika
By TradingEconomics
Turukapital	4B 13B
Eelmine avamishind	583.82
Eelmine sulgemishind	583.61

Uudiste sentiment

By Acuity

23%

77%

49 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

263.2 / 277.1 Toetus ja vastupanu

Madrigal Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. dets 2025, 23:21 UTC

Tulu

Omandamised, ülevõtmised, äriostud

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3. dets 2025, 23:14 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3. dets 2025, 22:01 UTC

Suurimad hinnamuutused turgudel

Costco Wholesale Reports Higher Monthly Sales

3. dets 2025, 21:38 UTC

Tulu

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3. dets 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3. dets 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. dets 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3. dets 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3. dets 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3. dets 2025, 23:10 UTC

Tulu

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3. dets 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3. dets 2025, 23:06 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3. dets 2025, 22:59 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy PC Financial From Loblaw for About $573.5M

3. dets 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3. dets 2025, 22:20 UTC

Tulu

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3. dets 2025, 22:19 UTC

Tulu

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3. dets 2025, 22:17 UTC

Tulu

Salesforce Working to Add Voice to Agentforce, CEO Says

3. dets 2025, 22:16 UTC

Tulu

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3. dets 2025, 22:15 UTC

Tulu

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3. dets 2025, 22:10 UTC

Omandamised, ülevõtmised, äriostud

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3. dets 2025, 22:09 UTC

Omandamised, ülevõtmised, äriostud

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. dets 2025, 21:49 UTC

Tulu

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. dets 2025, 21:23 UTC

Tulu

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3. dets 2025, 21:19 UTC

Tulu

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. dets 2025, 21:06 UTC

Tulu

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3. dets 2025, 21:04 UTC

Tulu

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3. dets 2025, 21:04 UTC

Tulu

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3. dets 2025, 21:03 UTC

Tulu

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Võrdlus sarnastega

Hinnamuutus

Madrigal Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

-1.99% langus

12 kuu keskmine prognoos

Keskmine 561.73 USD -1.99%

Kõrge 650 USD

Madal 445 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Madrigal Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Madrigal Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

263.2 / 277.1Toetus ja vastupanu

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

49 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.